Stelara* (Ustekinumab) — Medicare Part D spending
Janssen Biotech* · Rank #14 by total Part D spend · CMS data year 2023
Medicare Part D spent $2,987,778,600 on Stelara* (Ustekinumab) in 2023, the #14 drug by total Part D spending out of 3,598 drugs. That worked out to about $26,818.03 per dosage unit, $25,522 per claim and $130,300 per beneficiary, across 117,068 claims for 22,930 beneficiaries. Average spending per dosage unit rose +4.2% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Stelara* (Ustekinumab) spending at a glance (2023)
| Metric | Stelara* (Ustekinumab) |
|---|---|
| Total Part D spending (2023) | $2,987,778,600 |
| Total spending (2022) | $2,339,082,716 |
| Year-over-year change in total spending | +27.7% |
| Average spending per dosage unit (2023) | $26,818.03 |
| Change in spend per dosage unit (YoY) | +4.2% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +5.1% |
| Average spending per claim (2023) | $25,522 |
| Average spending per beneficiary (2023) | $130,300 |
| Total claims (2023) | 117,068 |
| Beneficiaries (2023) | 22,930 |
| Total dosage units (2023) | 238,312 |
| Manufacturer(s) | Janssen Biotech* |
| National rank by total spend (of 3,598 drugs) | #14 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $2,339,082,716 | $2,987,778,600 | +27.7% |
| Avg spend per dosage unit | $25,729.26 | $26,818.03 | +4.2% |
| Avg spend per claim | $24,121 | $25,522 | — |
| Avg spend per beneficiary | $117,136 | $130,300 | — |
| Total claims | 96,974 | 117,068 | — |
| Beneficiaries | 19,969 | 22,930 | — |
How Stelara* compares with nearby drugs
Drugs with total Part D spending closest to Stelara* (Ustekinumab):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Stelara* (Ustekinumab) (this drug, #14) | $2,987,778,600 | $26,818.03 | +4.2% |
| Lantus Solostar (Insulin Glargine,Hum.Rec.Anlog) (#12) | $3,157,233,282 | $30.28 | +3.8% |
| Biktarvy (Bictegrav/Emtricit/Tenofov Ala) (#13) | $3,152,256,269 | $133.13 | +5.5% |
| Xtandi (Enzalutamide) (#15) | $2,601,510,278 | $146.13 | +11.3% |
| Myrbetriq (Mirabegron) (#16) | $2,510,288,600 | $15.43 | +4.3% |
| Imbruvica (Ibrutinib) (#17) | $2,371,893,292 | $486.63 | +5.8% |
Frequently asked questions
How much does Medicare Part D spend on Stelara*?
Medicare Part D spent $2,987,778,600 on Stelara* (Ustekinumab) in 2023 (the latest CMS data year), across 117,068 claims for 22,930 beneficiaries. That ranks #14 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Stelara*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Stelara* (Ustekinumab) was $26,818.03. Compared with 2022 it rose +4.2%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Stelara*?
CMS attributes Stelara* (Ustekinumab) to Janssen Biotech* in the 2023 Part D spending file. Average spending per claim was $25,522 and per beneficiary $130,300.
Is the Stelara* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20